MOH Stock Analysis — Molina Healthcare
Sector: Healthcare
AI Verdict
You're paying a steep premium for a 50.5% earnings growth story, and unless Molina's government contract moat delivers exactly as promised, the stock looks expensive and vulnerable to a sharp correction.
Competitive Moat
Molina Healthcare specializes in managing Medicaid and government-sponsored health plans, leveraging long-standing contracts and regulatory expertise to maintain high barriers to entry. Its scale and operational experience in complex, cost-sensitive populations make it difficult for new entrants to compete profitably.
Summary
Molina is notable for its steep forward P/E of 47.2x, reflecting high expectations for a 50.5% jump in earnings next year.
Where It Stands
With an RSI of 81.5, shares are extremely overbought after an 8.78% one-year return, and the stock trades at 47.2x next year's earnings—more than double the healthcare sector median of 22x.
Key Metrics
- RSI: 81.5 — Overbought
- Trailing P/E: 71.1x
- Forward P/E: 47.2x
- PEG Ratio: 1.33
- Earnings Growth: +0.5%
- Revenue Growth: +0.1%
- Market Cap: $12.4B
- 1-Year Return: 8.78%
- 52-Week High: $243.77
- 52-Week Low: $121.06
Analyst Consensus
7 Buy · 17 Hold · 1 Sell (25 analysts)
Bull Case
Analysts expect a 50.5% EPS surge next year, which is built into the forward P/E of 47.2x, so if that growth materializes, the premium could be justified.
Bear Case
If the forward P/E compresses even halfway toward the sector median (from 47.2x to 22x), the stock could lose over 50% of its value, and the RSI of 81.5 signals a high risk of near-term pullback.
Catalyst to Watch
Watch for quarterly earnings and state Medicaid contract renewals—either missing growth targets or losing key contracts could break the high-multiple narrative.